Log in to search using one of your social media accounts:

 

UCLA study describes structure of tumor herpes virus associated with Kaposi ’s sarcoma
UCLA researchers have provided the first description of the structure of the herpes virus associated with Kaposi ’s sarcoma, a type of cancer.The discovery answers important questions about how the virus spreads and provides a potential roadmap for the development of antiviral drugs to combat both that virus and the more common Epstein-Barr virus, which is present in more than 90 percent of the adult population and is believed to have a nearly identical structure.In the study, published in the journal  Nature, the UCLA team showed in the laboratory that an inhibitor could be developed to break down the herpes vi...
Source: UCLA Newsroom: Health Sciences - January 20, 2018 Category: Universities & Medical Training Source Type: news

Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium WOODCLIFF LAKE, N.J., Jan. 19, 2018 -- (Healthcare Sales & Marketing ... Biopharmaceuticals, Oncology Eisai, REFLECT study, lenvatinib, Lenvima, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

European Commission Approves Amgen And Allergan's MVASI ® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab) First Biosimilar Bevacizumab Approved in the European Union THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with fluoropyrimidine-based chemotherapy for metastatic ...
Source: Amgen News Release - January 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New guideline for treatment of aggressive pituitary tumours
A new European clinical practice guideline for the treatment of aggressive pituitary tumours and carcinomas has been published in theEuropean Journal of Endocrinology.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 18, 2018 Category: Endocrinology Source Type: news

Radioactive Seed Localization or Wire-guided Localization of Nonpalpable Invasive and In Situ Breast Cancer: A Randomized, Multicenter, Open-label Trial
This research article has led to a Practice Changing Update in DynaMed Plus. It concludes that radioactive seed localization may have similar positive margin but higher successful placement rates compared to wire localization in women having breast-conserving surgery for nonpalpable invasive breast cancer or ductal carcinoma in situ (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 18, 2018 Category: Consumer Health News Source Type: news

Corynebacterium, Kingella Abundance Tied to HNSCC Risk
No correlation for overall microbiome composition with risk of head and neck squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 12, 2018 Category: Cancer & Oncology Tags: Oncology, ENT, Pathology, Journal, Source Type: news

Clinical Decision-Making for Immunotherapy in Metastatic RCC Clinical Decision-Making for Immunotherapy in Metastatic RCC
Should immunotherapy be considered as a first-line treatment strategy for metastatic renal cell carcinoma?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Certain factors may predict lung cancer patients' response to chemotherapy
(Wiley) In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 10, 2018 Category: Cancer & Oncology Source Type: news

5-FU Cream Reduces Surgery in High-Risk SCC Patients 5-FU Cream Reduces Surgery in High-Risk SCC Patients
Use of a topical 5-FU cream for patients with squamous cell carcinoma (SCC) reduces the need for surgery on their face and ears, although the chemopreventive effect wanes over time.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hydrochlorothiazide May Up Basal, Squamous Cell Cancer Risk
Increased risk for basal cell carcinoma, squamous cell carcinoma, with dose - response relationship (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 6, 2018 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Fluorouracil Tied to Reduced Surgery for Squamous Cell CA
Reduced risk of squamous cell carcinoma, but not basal cell carcinoma, for one year in at - risk veterans (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 5, 2018 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

A Little Dab'll Do Ya to Prevent Squamous Cell Carcinoma (CME/CE)
(MedPage Today) -- But side effects weren't negligible (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 4, 2018 Category: Dermatology Source Type: news

New cancer model shows genomic link between early-stage and invasive breast cancer types
(University of Texas M. D. Anderson Cancer Center) A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 4, 2018 Category: Biology Source Type: news

Predicting Prognosis in Submucosal Invasive Esophageal SCC Predicting Prognosis in Submucosal Invasive Esophageal SCC
This study sought to identify histopathological characteristics that could predict lymph node metastasis in submucosal invasive esophageal squamous cell carcinoma.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

In clinical trial, cream reduces squamous cell carcinoma risk
(Brown University) Results of a new randomized, double-blinded, controlled clinical trial in veterans showed a 75 percent reduction in the risk of needing surgery to treat a squamous cell carcinoma for a year after applying a skin cream for up to four weeks. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 3, 2018 Category: Cancer & Oncology Source Type: news

Lymphadenectomy in Renal Cell Carcinoma: No Benefit? Lymphadenectomy in Renal Cell Carcinoma: No Benefit?
A secondary analysis of the ASSURE trial reveals that lymph node removal does not improve survival in high-risk renal cell carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Atopic Dermatitis Associated With Higher Risk of Skin Cancer
Individuals with a history of atopic dermatitis have a higher risk of squamous cell carcinoma development (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 29, 2017 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Allergy, Nursing, Oncology, Pathology, Pediatrics, Journal, Source Type: news

Nanobiotix ’s nanoparticle-immunotherapy trial wins FDA approval
Nanobiotix (EMA:NANO) said today that the FDA has approved its IND application for a cancer trial combining its radiotherapy-activated nanoparticle tech with an anti-PD1 antibody. The Phase I/II trial is slated to evaluate the safety and efficacy of Nanobiotix’s NBTXR3 product administered with checkpoint inhibitors in three groups of patients with recurrent or metastatic head and neck squamous cell carcinoma or with metastatic non-small cell lung cancer. Get the full story at our sister site, Drug Delivery Business News. The post Nanobiotix’s nanoparticle-immunotherapy trial wins FDA approval appeare...
Source: Mass Device - December 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals Wall Street Beat nanobiotix Source Type: news

FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma
"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."01/02/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 22, 2017 Category: Urology & Nephrology Source Type: news

U.S. FDA Approval of CABOMETYX ® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.12/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2017 Category: Urology & Nephrology Source Type: news

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 19, 2017-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for the expanded indication of patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Results from Alliance CABOSUN trial lead to US FDA approval of extended indication
(Alliance for Clinical Trials in Oncology) The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 19, 2017 Category: Cancer & Oncology Source Type: news

Researchers find possible markers for earlier diagnosis of aggressive tongue cancer
(Case Western Reserve University) Squamous cell carcinoma of the tongue, also known as oral tongue cancer, is an aggressive form of cancer that generally affects older people. in a new study published in Oncotarget, a team of researchers has found that bacterial diversity and richness, and fungal richness, are significantly reduced in tumor tissue compared to their matched non-tumor tissues. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 19, 2017 Category: International Medicine & Public Health Source Type: news

Gaining insight into the molecular mechanisms behind squamous cell cancer
(Kanazawa University) Researchers at Kanazawa University report in EMBO Reports a new molecular mechanisms regulating cellular fate of squamous cell carcinomas. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 19, 2017 Category: Biology Source Type: news

EASL and AASLD Recommendations for the Diagnosis of HCC EASL and AASLD Recommendations for the Diagnosis of HCC
This study evaluated the diagnostic performance of CT, MRI and contrast-enhanced ultrasound, alone and in combination.Liver International (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 15, 2017 Category: Radiology Tags: Gastroenterology Journal Article Source Type: news

Frequent sun exposure may cue gene fusion found in skin cancer
(Kumamoto University) Researchers from Kumamoto University, Japan have determined that a particular fusion gene has a tendency to be found in cutaneous squamous cell carcinoma (cSCC) lesions on skin exposed frequently to the sun. The fusion gene is unique to cSCC and appears to be related to frequent sun exposure. It is believed that the work will open doors to a new form of personalized cSCC treatment. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 14, 2017 Category: Biology Source Type: news

NICE recommends Eisai ’s Kisplyx for renal cell carcinoma
Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.12/14/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2017 Category: Urology & Nephrology Source Type: news

Bayer receives approval in China for Stivarga ® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)
Approval based on data from the Phase III RESORCE study where Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - December 13, 2017 Category: Pharmaceuticals Source Type: news

13.12.17: Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancerApproval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 12, 2017 Category: Pharmaceuticals Source Type: news

Case: Metastatic Endometrial Serous Carcinoma to the Breast Case: Metastatic Endometrial Serous Carcinoma to the Breast
This unusual case underscores that while the breast is an atypical target of metastases, it is a possibility that needs to be considered, and should be confirmed histologically.Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2017 Category: Pharmaceuticals Source Type: news

Immunotherapy for Merkel cell carcinoma -- novel research highlights quality of life benefits
(Future Science Group) Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

Dr. Escudier: The Future of RCC Treatment
Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. He is a member of the Kidney Cancer Association Professional Group and formerly a member of its Medical& Scientific Steering Committee. His research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutics.12/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 7, 2017 Category: Urology & Nephrology Source Type: news

Research Finds Popular Blood Pressure Drug Increases Skin Cancer Risk
This study shows a possible link between HCTZ and basal cell and squamous cell carcinomas of the skin. These are not melanomas, the deadliest form of skin cancer, but they both can pose serious health risks. This study shows an association between HCTZ and skin cancer, not proof that the medication actually causes cancer, but it’s link that needs to be studied further. In the meantime, continue to take your blood pressure medication and protect yourself from excessive sun exposure. (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 6, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Dr. Mallika Marshall Source Type: news

Preoperative Cholesterol Level Is Associated With Worse Pathological Outcomes
In this study, we aimed to investigate the relationship between preoperative cholesterol level (PCL) and postoperative outcomes of patients with localized RCC.12/06/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 6, 2017 Category: Urology & Nephrology Source Type: news

IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks
Focal adhesion kinase (FAK) mediates tumor cell–intrinsic behaviors that promote tumor growth and metastasis. We previously showed that FAK also induces the expression of inflammatory genes that inhibit antitumor immunity in the microenvironment. We identified a crucial, previously unknown role for the dual-function cytokine interleukin-33 (IL-33) in FAK-dependent immune evasion. In murine squamous cell carcinoma (SCC) cells, specifically nuclear FAK enhanced the expression of the genes encoding IL-33, the chemokine CCL5, and the soluble, secreted form of the IL-33 receptor, called soluble ST2 (sST2). The abundance o...
Source: Signal Transduction Knowledge Environment - December 5, 2017 Category: Science Authors: Serrels, B., McGivern, N., Canel, M., Byron, A., Johnson, S. C., McSorley, H. J., Quinn, N., Taggart, D., Von Kreigsheim, A., Anderton, S. M., Serrels, A., Frame, M. C. Tags: STKE Research Articles Source Type: news

Tobacco Smoking Associated with Poor Survival Following Head and Neck Cancer Diagnosis
Researchers found a statistically significant difference in median survival time between smokers and nonsmokers at diagnosis of head and neck squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Head & Neck Cancer News Source Type: news

Primary Small Cell Carcinoma of the Breast: A Case Report Primary Small Cell Carcinoma of the Breast: A Case Report
This case report sheds light on small cell carcinoma of the breast, a rarely described subtype of neuroendocrine breast cancer, providing a comprehensive approach to diagnosis and management.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Mother has a hole in her face due to skin cancer
Keely Jones, 40, from North Carolina, was advised by a beautician to get a red blemish on her face seen to. She was finally diagnosed with basal cell carcinoma two months ago. (Source: the Mail online | Health)
Source: the Mail online | Health - November 28, 2017 Category: Consumer Health News Source Type: news

HCC in Chronic HBV vs Chronic HCV After Virologic Response HCC in Chronic HBV vs Chronic HCV After Virologic Response
Does the achievement of virologic response modify the risk of hepatocellular carcinoma differently in patients with chronic hepatitis B as compared to those with chronic hepatitis C?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 28, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

ECC 2015: GIOTRIF ® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status
ECC 2015: GIOTRIF ® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Sentinel Node Biopsy for High-Risk Squamous Cell Carcinoma Sentinel Node Biopsy for High-Risk Squamous Cell Carcinoma
Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - November 22, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Elevated Liver Cancer, Death Rates With Chronic HBV Elevated Liver Cancer, Death Rates With Chronic HBV
Patients with immune-tolerant-phase chronic hepatitis B virus (HBV) infection, who are usually not considered for treatment, face an increased risk of hepatocellular carcinoma (HCC) and death, compared with treated immune-active-phase patients, researchers from Korea report.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 22, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

NAFLD Linked to Increased Cancer Incidence Rate
NAFLD strongly tied to development of hepatocellular carcinoma, CRC in males, breast cancer in females (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 20, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Radiology, Journal, Source Type: news

FDA Approves First Adjuvant Therapy for Renal Cell Carcinoma
The FDA has approved sunitinib malate (Sutent) as an adjuvant therapy for adults at risk for recurrent renal cell carcinoma following nephrectomy. Sunitinib, a kinase... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news

FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.11/30/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 19, 2017 Category: Urology & Nephrology Source Type: news

Endoscopy Could Spare More Barrett's Patients From Surgery Endoscopy Could Spare More Barrett's Patients From Surgery
For patients with Barrett's esophagus, endoscopy, a recognized treatment for high-grade dysplasia, is just as effective for intramucosal carcinoma, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

FDA OKs First Adjuvant Treatment for Kidney Cancer FDA OKs First Adjuvant Treatment for Kidney Cancer
Sunitinib is now approved for use after surgery in renal cell carcinoma patients who are at high risk for disease recurrence.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
November 16, 2017 -- The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2017 Category: Drugs & Pharmacology Source Type: news